MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors
International Journal of Clinical Oncology · 2024
DOI: 10.1007/s10147-024-02477-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Hirotaka Nagasaka und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Interleukin-6, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Few studies have reported reliable prognostic factors for immune checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC). Therefore, we investigated prognostic factors in patients treated with ICIs for unresectable or metastatic RCC.
Methods
We included 43 patients who received ICI treatment for RCC between January 2018 and October 2021. Blood samples were drawn before treatment, and 73 soluble factors in the plasma were analyzed using a bead-based multiplex assay. We examined factors associated with progression-free survival (PFS), overall survival (OS), and immune-related adverse events (irAE) using the Chi-squared test, Kaplan–Meier method, and the COX proportional hazards model.
Results
Patients exhibited a median PFS and OS of 212 and 783 days, respectively. Significant differences in both PFS and OS were observed for MMP1 (PFS, p < 0.001; OS, p = 0.003), IL-1β (PFS, p = 0.021; OS, p = 0.008), sTNFR-1 (PFS, p = 0.017; OS, p = 0.005), and IL-6 (PFS, p = 0.004; OS, p < 0.001). Multivariate analysis revealed significant differences in PFS for MMP1 (hazard ratio [HR] 5.305, 95% confidence interval [CI], 1.648–17.082; p = 0.005) and OS for IL-6 (HR 23.876, 95% CI, 3.426–166.386; p = 0.001). Moreover, 26 patients experienced irAE, leading to ICI discontinuation or withdrawal. MMP1 was significantly associated with irAE (p = 0.039).
Conclusion
MMP1 may be associated with severe irAE, and MMP1, IL-1β, sTNFR-1, and IL-6 could serve as prognostic factors in unresectable or metastatic RCC treated with ICIs. MMP1 and IL-6 were independent predictors of PFS and OS, respectively. Thus, inhibiting these soluble factors may be promising for enhancing antitumor responses in patients with RCC treated with ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
- Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan. kishidat@kcch.jp.
- Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, 241-8515, Japan.
- Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Kanagawa, Japan.
- Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, 241-8515, Japan. tsasada@kcch.jp.
- Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Kanagawa, Japan. tsasada@kcch.jp.
Zitieren
APA
Nagasaka, H., Kishida, T., Kouro, T., Igarashi, Y., Takebe, S., Yamamoto, S., Kondo, T., Koizumi, M., Terao, H., Suzuki, T., Nakaigawa, N., Himuro, H., Wei, F., & Sasada, T. (2024). MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02477-4
Vancouver
Nagasaka H, Kishida T, Kouro T, Igarashi Y, Takebe S, Yamamoto S, et al. MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02477-4
BibTeX
@article{Nagasaka2024,
author = {Nagasaka, Hirotaka and Kishida, Takeshi and Kouro, Taku and Igarashi, Yuka and Takebe, Shinichi and Yamamoto, Shotaro and Kondo, Takuya and Koizumi, Mitsuyuki and Terao, Hideyuki and Suzuki, Takahisa and Nakaigawa, Noboru and Himuro, Hidetomo and Wei, Feifei and Sasada, Tetsuro},
title = {MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors},
journal = {International Journal of Clinical Oncology},
year = {2024},
doi = {10.1007/s10147-024-02477-4}
}
EUVIMED